A Four-Day Cure: How a Patented Cream Could Remap Skin Cancer Prevention

FORT LAUDERDALE, Fla. – July 22, 2026 – In a move poised to reshape a significant corner of the dermatology market, the innovation firm SKNV has secured exclusive commercialization rights to a breakthrough skin cancer prevention therapy from Washington University in St. Louis. The deal centers on a patented combination cream that reduces treatment for a common precancerous condition from several weeks to a mere four days, a development with profound implications for millions of Americans at risk for skin cancer.

The therapy, marketed by SKNV as Kefunova™ Cream, combines two existing drugs—Fluorouracil and Calcipotriene—to treat Actinic Keratosis (AK), a form of sun damage that can progress to squamous cell carcinoma (SCC), the second most common skin cancer. By acquiring the exclusive sub-license, SKNV is not just adding a product to its portfolio; it is taking control of a technology that challenges conventional treatment paradigms and leverages a nimble, and often misunderstood, corner of the pharmaceutical industry.

A Paradigm Shift in Patient Care

For decades, the standard of care for widespread Actinic Keratosis has involved topical treatments that, while effective, come with a significant burden. Patients have typically faced treatment regimens lasting two to four weeks, often accompanied by harsh side effects like redness, inflammation, and crusting that make adherence a major challenge. This is where the Washington University-developed combination therapy marks a radical departure.

Clinical trials have demonstrated that the combination cream achieves superior results in just four days. This dramatic reduction in treatment time is more than a matter of convenience; it directly addresses patient adherence, a critical factor in successful medical outcomes. "Previously, topical field therapy with Fluorouracil monotherapy was impractical for many AK patients, due to the lengthy treatment regimen and harsh side effects," said Shawn Demehri, MD, PhD, a co-inventor of the technology and Director of the High Risk Skin Cancer Clinic at Massachusetts General Hospital.

This new approach embodies the principle of "field-directed therapy," a strategy gaining prominence in dermatology. Instead of just treating individual, visible AK lesions, the therapy treats the entire "field" of sun-damaged skin, addressing unseen, subclinical damage that may already be on a path to becoming cancerous. "When treating patients with AKs, it's not just about targeting the visible lesions," explained Lynn A. Cornelius, MD, Division Chief of Dermatology at Washington University and a co-inventor. "It's also about getting ahead of the unseen actinic damage... subclinical AKs harbor a mutational profile indicative of a potentially cancerous state."

This clinical advancement has already earned recognition from key medical bodies. In April 2026, the International Immunosuppression and Transplant Skin Cancer Collaborative (ITSCC) recommended the short-course combination therapy for treating AK, and its methodology aligns with recent guidelines from the American Academy of Dermatology. This expert validation underscores the therapy's potential to become a new standard of care.

The Science of Synergistic Immunity

The therapy’s effectiveness lies not just in its speed, but in its elegant, dual-mechanism approach that transforms a standard chemotherapy treatment into a targeted immunotherapy. The two active ingredients work in synergy to activate the body's own immune system against damaged cells.

First, Fluorouracil (5-FU), a long-established cytotoxic agent, works by inducing cell death in the rapidly dividing, sun-damaged skin cells. This process causes the dying cells to release tumor antigens. In essence, it flags the enemy. The second component, Calcipotriene—a synthetic vitamin D analog—then acts as a powerful immune stimulant. It triggers the production of a signaling protein called TSLP, which in turn recruits an army of CD4+ T cells to the skin. These T cells recognize the antigens released by the 5-FU and mount a potent, targeted attack on the precancerous cells.

Even more significantly, follow-up studies tracking patients for over three years revealed a lasting benefit. The treatment not only cleared existing AKs but also reduced the risk of developing new squamous cell carcinomas in the treated areas. Researchers found this long-term protection was associated with the persistence of "tissue-resident memory T (TRM) cells" in the skin. The therapy doesn't just clear the field; it leaves behind a long-term immune surveillance system, a novel immunopreventive effect that represents a major leap forward.

SKNV’s Strategic Play: The 503B Advantage

The story behind Kefunova’s path to market is as innovative as its science. SKNV operates not as a traditional pharmaceutical giant but as an FDA-Registered 503B Outsourcing Facility. This designation allows the company to compound medications on a larger scale than a typical pharmacy, adhering to the same Current Good Manufacturing Practices (CGMP) required of major drug makers, ensuring consistency and quality.

However, this regulatory pathway comes with a critical distinction noted in SKNV’s own disclaimer: drugs from 503B facilities are not individually reviewed or approved by the FDA for safety and efficacy in the same way new drugs are. They are exempt from the lengthy and costly clinical trial process required for a New Drug Application (NDA).

This model provides SKNV with a unique strategic advantage. It can bring innovative, clinically-researched formulations like the 5-FU/Calcipotriene combination to market far more quickly and with less capital expenditure. It also allows the company to bypass many of the commercial hurdles that plague conventional drug launches, such as navigating restrictive insurance formularies and prior authorization requirements. By offering direct-to-patient shipping and clear, upfront pricing, SKNV aims to streamline access for both doctors and patients. This strategy appears to be paying off.

"Since its introduction in 2025, Kefunova rapidly became the most prescribed medication across our portfolio of more than 100 formulations, underscoring the strong clinical interest in this patented treatment approach," said Dr. Spencer Malkin, Founder and CEO of SKNV. The exclusive license from Washington University now solidifies the company’s market position, protecting its flagship product from direct competition and ensuring it remains the sole provider of this specific, highly researched combination.

Reshaping the Dermatological Market

With approximately 40 million new cases of Actinic Keratosis diagnosed annually in the U.S., the market for effective treatments is substantial. By securing the rights to a therapy that is faster, more convenient, and offers long-term preventative benefits, SKNV is poised for significant disruption. The company’s 503B business model challenges the established pharmaceutical distribution chain, offering an alternative path that prioritizes speed to market and direct access.

This combination of scientific innovation and a disruptive commercialization strategy places SKNV at a compelling crossroads. While competitors must navigate the multi-year, billion-dollar FDA approval pipeline, SKNV is already delivering a therapy backed by robust academic research directly to a network of thousands of providers. The success of Kefunova demonstrates a powerful demand for therapies that not only improve clinical outcomes but also simplify the increasingly complex process of receiving care. This strategic alignment of cutting-edge science with a nimble business model may well provide a blueprint for the future of specialized medical innovation.